Charles Schwab
CGEM icon

Charles Schwab’s Cullinan Oncology CGEM Stock Holding History

Charles Schwab’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.45M Buy
464,034
+31,141
+7% +$462K ﹤0.01% 2237
2026
Q1 		$6.15M Sell
432,893
-3,380
-0.8% -$43.4K ﹤0.01% 2315
2025
Q4 		$4.52M Buy
436,273
+33,635
+8% +$303K ﹤0.01% 2497
2025
Q3 		$2.39M Sell
402,638
-32,878
-8% -$241K ﹤0.01% 2708
2025
Q2 		$3.28M Buy
435,516
+11,254
+3% +$90.4K ﹤0.01% 2506
2025
Q1 		$3.21M Sell
424,262
-6,709
-2% -$64.4K ﹤0.01% 2457
2024
Q4 		$5.25M Buy
430,971
+7,012
+2% +$101K ﹤0.01% 2315
2024
Q3 		$7.1M Buy
423,959
+53,328
+14% +$946K ﹤0.01% 2192
2024
Q2 		$6.46M Buy
370,631
+112,758
+44% +$2.4M ﹤0.01% 2238
2024
Q1 		$4.39M Buy
257,873
+11,168
+5% +$173K ﹤0.01% 2333
2023
Q4 		$2.51M Buy
246,705
+16,719
+7% +$148K ﹤0.01% 2545
2023
Q3 		$2.08M Buy
229,986
+44,200
+24% +$460K ﹤0.01% 2585
2023
Q2 		$2M Sell
185,786
-1,747
-0.9% -$18.6K ﹤0.01% 2548
2023
Q1 		$1.92M Sell
187,533
-33,033
-15% -$364K ﹤0.01% 2537
2022
Q4 		$2.33M Buy
220,566
+3,028
+1% +$36.8K ﹤0.01% 2521
2022
Q3 		$2.79M Buy
217,538
+31,765
+17% +$428K ﹤0.01% 2481
2022
Q2 		$2.38M Buy
185,773
+7,623
+4% +$86.4K ﹤0.01% 2517
2022
Q1 		$1.87M Buy
178,150
+3,937
+2% +$53.2K ﹤0.01% 2668
2021
Q4 		$2.69M Buy
174,213
+3,469
+2% +$69.2K ﹤0.01% 2602
2021
Q3 		$3.85M Buy
170,744
+81,045
+90% +$2.17M ﹤0.01% 2490
2021
Q2 		$2.31M Buy
89,699
+3,268
+4% +$100K ﹤0.01% 2668
2021
Q1 		$3.6M Buy
+86,431
New +$3.51M ﹤0.01% 2451

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Charles Schwab's CGEM Position: Q2 2026 in Review

Charles Schwab increased its Cullinan Oncology (CGEM) stake by 7.2% in Q2 2026, buying an estimated $462K and bringing the position to 464,034 shares worth $8.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Charles Schwab first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Charles Schwab held 464,034 shares of Cullinan Oncology worth $8.45M as of Q2 2026.
  • Charles Schwab bought 31,141 Cullinan Oncology shares in Q2 2026, an estimated $462K.
  • Cullinan Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2237 holding.
  • Charles Schwab first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.